https://www.selleckchem.com/pr....oducts/rocaglamide.h
001). For cases of grade 1-2 disease, older patients had a higher proportion of the luminal B subtype (49% vs. 30%, p=0.014). Age≥75 predicted for inferior OS (HR=3.06, p0.001). The luminal B subtype predicted for inferior OS (HR=2.12, p=0.014), RFi (HR 5.02, p0.001), and LRR (HR=3.12, p=0.045). There were no significant differences in individual gene expression between the two groups. Women with ER+/HER2- breast cancer ≥75years old had higher rates of the more aggressive luminal B subtype and inferior outcomes. Genomic test
Like
Comment
Share
